Want to see HK:1541 full AI Analyst Report?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (1541) Revenue
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Revenue
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H had a revenue of 37.25M in the quarter ending Jun 30, 2026, with -67.42%. This bring the company's revenue in the last twelve months to 151.57M, Decreased 4.27%. In the fiscal year ending Dec 31, 2025, ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H had annual revenue of 150.30M with 102.70% growth.
- Revenue (ttm)
- 151.57M
- Revenue Growth
- 28.93%
- P/S Ratio
- 8.33
- Revenue/Employee
- HKD 744,063
- Employees
- 202
- Market Cap
- HKD 1.25B
Revenue Chart
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Revenue - Annual
Revenue History
| Fiscal End Date | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 150.30M | 76.15M | 102.70% |
| Dec 31, 2024 | 74.15M | 73.76M | 19109.59% |
| Dec 31, 2023 | 386.00K | -5.30M | -93.22% |
| Dec 31, 2022 | 5.69M | -8.12M | -58.79% |
| Dec 31, 2021 | 13.81M | ― | ― |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.